Patents by Inventor Toshihiro Imaeda

Toshihiro Imaeda has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Nitrogen-containing heterocyclic compound
    Patent number: 10214508
    Abstract: The present invention provides a compound having a cholinergic muscarinic M1 receptor positive allosteric modulator activity and useful as a medicament such as a prophylactic or therapeutic drug for Alzheimer's disease, schizophrenia, pain, sleep disorder, Parkinson's disease dementia, dementia with Lewy bodies and the like, and the like. The present invention relates to a compound represented by the formula (I) or a salt thereof. wherein each symbol is as described in the attached DESCRIPTION.
    Type: Grant
    Filed: June 11, 2015
    Date of Patent: February 26, 2019
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Masaki Ogino, Eiji Kimura, Shinkichi Suzuki, Tomoko Ashizawa, Toshihiro Imaeda, Ikuo Fujimori, Ryosuke Arai
  • Heterocyclic compound
    Patent number: 10131653
    Abstract: The present invention provide a compound having an orexin receptor antagonistic activity, which is expected to be useful as medicaments such as agents for the prophylaxis or treatment of sleep disorder, depression, anxiety disorder, panic disorder, schizophrenia, drug dependence, Alzheimer's disease and the like. The present invention relates to a compound represented by the formula (I): wherein each symbol is as defined in the specification, or a salt thereof.
    Type: Grant
    Filed: April 22, 2016
    Date of Patent: November 20, 2018
    Assignee: TAKEDA PHARMACEUTICAL COMPANY LIMITED
    Inventors: Taku Kamei, Yasuyoshi Arikawa, Tomohiro Ohashi, Toshihiro Imaeda, Ikuo Fujimori, Takashi Miki, Jinichi Yonemori, Yuya Oguro, Takahiro Sugimoto, Masaki Seto, Goushi Nishida, Makoto Kamata, Hiroshi Imoto
  • HETEROCYCLIC COMPOUND AND USE THEREOF
    Publication number: 20180162875
    Abstract: Provided is a compound represented by the formula (I): wherein each symbol is as defined in the specification, or a salt thereof, which has an AMPA (?-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid) receptor potentiating action. The compound of the present invention is useful as a prophylactic or therapeutic drug for depression, schizophrenia, Alzheimer's disease or attention deficit hyperactivity disorder (ADHD) and the like.
    Type: Application
    Filed: December 18, 2017
    Publication date: June 14, 2018
    Inventors: Masakuni KORI, Toshihiro IMAEDA, Shinji NAKAMURA, Masashi TOYOFUKU, Eiji HONDA, Yasutomi ASANO, Osamu UJIKAWA, Michiyo MOCHIZUKI
  • Heterocyclic Compound
    Publication number: 20180155333
    Abstract: The present invention provide a compound having an orexin receptor antagonistic activity, which is expected to be useful as medicaments such as agents for the prophylaxis or treatment of sleep disorder, depression, anxiety disorder, panic disorder, schizophrenia, drug dependence, Alzheimer's disease and the like. The present invention relates to a compound represented by the formula (I): wherein each symbol is as defined in the specification, or a salt thereof.
    Type: Application
    Filed: April 22, 2016
    Publication date: June 7, 2018
    Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED
    Inventors: Taku KAMEI, Yasuyoshi ARIKAWA, Tomohiro OHASHI, Toshihiro IMAEDA, Ikuo FUJIMORI, Takashi MIKI, Jinichi YONEMORI, Yuya OGURO, Takahiro SUGIMOTO, Masaki SETO, Goushi NISHIDA, Makoto KAMATA, Hiroshi IMOTO
  • Heterocyclic compound and use thereof
    Patent number: 9884875
    Abstract: Provided is a compound represented by the formula (I): wherein each symbol is as defined in the specification, or a salt thereof, which has an AMPA (?-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid) receptor potentiating action. The compound of the present invention is useful as a prophylactic or therapeutic drug for depression, schizophrenia, Alzheimer's disease or attention deficit hyperactivity disorder (ADHD) and the like.
    Type: Grant
    Filed: October 10, 2016
    Date of Patent: February 6, 2018
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Masakuni Kori, Toshihiro Imaeda, Shinji Nakamura, Masashi Toyofuku, Eiji Honda
  • NITROGEN-CONTAINING HETEROCYCLIC COMPOUND
    Publication number: 20170121308
    Abstract: The present invention provides a compound having a cholinergic muscarinic M1 receptor positive allosteric modulator activity and useful as a medicament such as a prophylactic or therapeutic drug for Alzheimer's disease, schizophrenia, pain, sleep disorder, Parkinson's disease dementia, dementia with Lewy bodies and the like, and the like. The present invention relates to a compound represented by the formula (I) or a salt thereof. wherein each symbol is as described in the attached DESCRIPTION.
    Type: Application
    Filed: June 11, 2015
    Publication date: May 4, 2017
    Inventors: Masaki OGINO, Eiji KIMURA, Shinkichi SUZUKI, Tomoko ASHIZAWA, Toshihiro IMAEDA, Ikuo FUJIMORI, Ryosuke ARAI
  • HETEROCYCLIC COMPOUND AND USE THEREOF
    Publication number: 20170022222
    Abstract: Provided is a compound represented by the formula (I): wherein each symbol is as defined in the specification, or a salt thereof, which has an AMPA (?-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid) receptor potentiating action. The compound of the present invention is useful as a prophylactic or therapeutic drug for depression, schizophrenia, Alzheimer's disease or attention deficit hyperactivity disorder (ADHD) and the like.
    Type: Application
    Filed: October 10, 2016
    Publication date: January 26, 2017
    Inventors: Masakuni KORI, Toshihiro IMAEDA, Shinji NAKAMURA, Masashi TOYOFUKU, Eiji HONDA, Yasutomi ASANO, Osamu UJIKAWA, Michiyo MOCHIZUKI
  • Sulfonamide derivative and use thereof
    Patent number: 9527807
    Abstract: Provided is a compound having an AMPA receptor function enhancing action, and useful as a prophylactic or therapeutic drug for depression, Alzheimer's disease, schizophrenia, attention deficit hyperactivity disorder (ADHD) and the like. A compound represented by the formula (I): wherein each symbol is as defined in the present specification, or a salt thereof.
    Type: Grant
    Filed: April 5, 2012
    Date of Patent: December 27, 2016
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Shoji Fukumoto, Osamu Ujikawa, Shinji Morimoto, Yasutomi Asano, Satoshi Mikami, Norihito Tokunaga, Masakuni Kori, Toshihiro Imaeda, Koichiro Fukuda, Shinji Nakamura, Kouichi Iwanaga
  • Heterocyclic compound and use thereof
    Patent number: 9499568
    Abstract: Provided is a compound represented by the formula (I): wherein each symbol is as defined in the specification, or a salt thereof, which has an AMPA (?-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid) receptor potentiating action. The compound of the present invention is useful as a prophylactic or therapeutic drug for depression, schizophrenia, Alzheimer's disease or attention deficit hyperactivity disorder (ADHD) and the like.
    Type: Grant
    Filed: July 21, 2015
    Date of Patent: November 22, 2016
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Masakuni Kori, Toshihiro Imaeda, Shinji Nakamura, Masashi Toyofuku, Eiji Honda, Osamu Ujikawa
  • HETEROCYCLIC COMPOUND
    Publication number: 20160264536
    Abstract: The problem of the present invention is to provide a compound having a PDE2A inhibitory action, and useful as a prophylactic or therapeutic drug for schizophrenia, Alzheimer's disease and the like. The present invention relates to a compound represented by the formula (I): wherein each symbol is as described in the DESCRIPTION, or a salt thereof.
    Type: Application
    Filed: October 22, 2014
    Publication date: September 15, 2016
    Inventors: Masaki SETO, Yoshihiro BANNO, Toshihiro IMAEDA, Yuichi KAJITA, Tomoko ASHIZAWA, Masanori KAWASAKI, Shinji NAKAMURA, Satoshi MIKAMI, Izumi NOMURA, Takahiko TANIGUCHI, Shogo MARUI
  • HETEROCYCLIC COMPOUND
    Publication number: 20160251352
    Abstract: The present invention provides a compound having a superior JAK inhibitory action, which is useful as an agent for the prophylaxis or treatment of autoimmune diseases (rheumatoid arthritis, psoriasis, inflammatory bowel disease, Sjogren's syndrome, Behcet's disease, multiple sclerosis, systemic lupus erythematosus, etc.), cancer (leukemia, uterine leiomyosarcoma, prostate cancer, multiple myeloma, cachexia, myelofibrosis, etc.) and the like, or a salt thereof. The present invention relates to a compound represented by the formula wherein each symbol is as defined in the specification, or a salt thereof.
    Type: Application
    Filed: May 6, 2016
    Publication date: September 1, 2016
    Inventors: Hiroshi NARA, Masaki DAINI, Akira KAIEDA, Taku KAMEI, Toshihiro IMAEDA, Fumiaki KIKUCHI
  • Heterocyclic compound
    Patent number: 9371320
    Abstract: The present invention provides a compound having a superior JAK inhibitory action, which is useful as an agent for the prophylaxis or treatment of autoimmune diseases (rheumatoid arthritis, psoriasis, inflammatory bowel disease, Sjogren's syndrome, Behcet's disease, multiple sclerosis, systemic lupus erythematosus, etc.), cancer (leukemia, uterine leiomyosarcoma, prostate cancer, multiple myeloma, cachexia, myelofibrosis, etc.) and the like, or a salt thereof. The present invention relates to a compound represented by the formula wherein each symbol is as defined in the specification, or a salt thereof.
    Type: Grant
    Filed: May 31, 2013
    Date of Patent: June 21, 2016
    Assignee: TAKEDA PHARMACEUTICAL COMPANY LIMITED
    Inventors: Hiroshi Nara, Masaki Daini, Akira Kaieda, Toshihiro Imaeda, Fumiaki Kikuchi
  • HETEROCYCLIC COMPOUND
    Publication number: 20160159808
    Abstract: A compound represented by the formula (I): wherein each symbol is as described in the SPECIFICATION, or a salt thereof has a PDE2A inhibitory action, and is useful as a prophylactic or therapeutic drug for schizophrenia, Alzheimer's disease and the like.
    Type: Application
    Filed: July 23, 2014
    Publication date: June 9, 2016
    Inventors: Masanori Kawasaki, Satoshi Mikami, Shinji Nakamura, Nobuyuki Negoro, Shuhei Ikeda, Izumi Nomura, Tomoko Ashizawa, Toshihiro Imaeda, Masaki Seto, Shigekazu Sasaki, Shogo Marui, Takahiko Taniguchi
  • HETEROCYCLIC COMPOUND AND USE THEREOF
    Publication number: 20150353578
    Abstract: Provided is a compound represented by the formula (I): wherein each symbol is as defined in the specification, or a salt thereof, which has an AMPA (?-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid) receptor potentiating action. The compound of the present invention is useful as a prophylactic or therapeutic drug for depression, schizophrenia, Alzheimer's disease or attention deficit hyperactivity disorder (ADHD) and the like.
    Type: Application
    Filed: July 21, 2015
    Publication date: December 10, 2015
    Inventors: Masakuni KORI, Toshihiro IMAEDA, Shinji NAKAMURA, Masashi TOYOFUKU, Eiji HONDA, Yasutomi ASANO, Osamu UJIKAWA, Michiyo MOCHIZUKI
  • Heterocyclic compound and use thereof
    Patent number: 9150591
    Abstract: Provided is a compound represented by the formula (I): wherein each symbol is as defined in the specification, or a salt thereof, which has an AMPA (?-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid) receptor potentiating action. The compound of the present invention is useful as a prophylactic or therapeutic drug for depression, schizophrenia, Alzheimer's disease or attention deficit hyperactivity disorder (ADHD) and the like.
    Type: Grant
    Filed: August 9, 2011
    Date of Patent: October 6, 2015
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Masakuni Kori, Toshihiro Imaeda, Shinji Nakamura, Masashi Toyofuku, Eiji Honda, Osamu Ujikawa
  • HETEROCYCLIC COMPOUND
    Publication number: 20150141406
    Abstract: The present invention provides a compound having a superior JAK inhibitory action, which is useful as an agent for the prophylaxis or treatment of autoimmune diseases (rheumatoid arthritis, psoriasis, inflammatory bowel disease, Sjogren's syndrome, Behcet's disease, multiple sclerosis, systemic lupus erythematosus, etc.), cancer (leukemia, uterine leiomyosarcoma, prostate cancer, multiple myeloma, cachexia, myelofibrosis, etc.) and the like, or a salt thereof. The present invention relates to a compound represented by the formula wherein each symbol is as defined in the specification, or a salt thereof.
    Type: Application
    Filed: May 31, 2013
    Publication date: May 21, 2015
    Inventors: Hiroshi Nara, Masaki Daini, Akira Kaieda, Taku Kamei, Toshihiro Imaeda, Fumiaki Kikuchi
  • HETEROCYCLIC COMPOUND AND USE THEREOF
    Publication number: 20150073137
    Abstract: Provided is a compound represented by the formula (I): wherein each symbol is as defined in the specification, or a salt thereof, which has an AMPA (?-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid) receptor potentiating action. The compound of the present invention is useful as a prophylactic or therapeutic drug for depression, schizophrenia, Alzheimer's disease or attention deficit hyperactivity disorder (ADHD) and the like.
    Type: Application
    Filed: November 13, 2014
    Publication date: March 12, 2015
    Inventors: Masakuni KORI, Toshihiro IMAEDA, Shinji NAKAMURA, Masashi TOYOFUKU, Eiji HONDA, Yasutomi ASANO, Osamu UJIKAWA, Michiyo MOCHIZUKI
  • Heterocyclic compound and use thereof
    Patent number: 8916551
    Abstract: Provided is a compound represented by the formula (I): wherein each symbol is as defined in the specification, or a salt thereof, which has an AMPA (?-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid) receptor potentiating action. The compound of the present invention is useful as a prophylactic or therapeutic drug for depression, schizophrenia, Alzheimer's disease or attention deficit hyperactivity disorder (ADHD) and the like.
    Type: Grant
    Filed: February 22, 2013
    Date of Patent: December 23, 2014
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Masakuni Kori, Toshihiro Imaeda, Shinji Nakamura, Masashi Toyofuku, Eiji Honda
  • Heterocyclic compound and use thereof
    Patent number: 8778934
    Abstract: Provided is a compound represented by the formula (I): wherein each symbol is as defined in the specification, or a salt thereof, which has an AMPA (?-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid) receptor potentiating action. The compound of the present invention is useful as a prophylactic or therapeutic drug for depression, schizophrenia, Alzheimer's disease or attention deficit hyperactivity disorder (ADHD) and the like.
    Type: Grant
    Filed: February 22, 2013
    Date of Patent: July 15, 2014
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Masakuni Kori, Toshihiro Imaeda, Shinji Nakamura, Masashi Toyofuku, Eiji Honda, Yasutomi Asano, Osamu Ujikawa, Michiyo Mochizuki
  • Automobile
    Patent number: D742790
    Type: Grant
    Filed: October 24, 2014
    Date of Patent: November 10, 2015
    Assignee: MITSUBISHI JIDOSHA KOGYO KABUSHIKI KAISHA
    Inventors: Hiroshi Noguchi, Toshihiro Imaeda, Yutaka Iwata